2025 Q4 -tulosraportti
Vain PDF
10 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 480 | - | - | ||
| 515 | - | - | ||
| 82 | - | - | ||
| 393 | - | - | ||
| 7 050 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·7 min sitten · MuokattuThe rights issue cancelled. It is not necessary to dilute the shareholders with a rights issue at kr. 10,80, especially not if the management also believes that the share price will rise. A share price increase will benefit all shareholders with an increase in value on a lower number of shares. Largest shareholder HØSE AS secured themselves against dilution in the 250 mill issue. They bought shares last Thursday at around 6-7. He stated that to Finansavisen. Everyone has had the opportunity to do the same, and if the price is under 10,80 at market open on Monday, the opportunity is still there. I interpret the timing of the announcement such that the management does not believe it will last going forward with a price under 10,80 and that they foresee a share price increase. Therefore, they announce while the price is still lower and Monday / Tuesday can change this. They don't need money. PS be prepared that the ASGCT announcement possibly won't come before Tuesday morning as the release time is 22.30 Norwegian time Monday as a nice person ENordfra reminded. Then the opportunity to buy is present all Monday if someone wishes it and the price is under 10,80. I believe that is the logic behind the timing of the announcement from the management last night.·2 min sittenWrong, they have enough until 2030 such decisions have been made at all general meetings in recent years. It can provide flexibility in negotiations on agreements combined with an ownership stake in the company. All options must be kept open even if they don't materialize..- ·11 min sitten · MuokattuMonday - possibly after market close, due to the time difference, there will probably be a short message with info about what will be presented at ASGCT in May. Could yesterday evening's message be a premonition that CNS is the topic? This is an important sentence in yesterday's message: The project involves testing of Circio’s circVec circular RNA expression technology for delivery with AAV vectors in a specific therapeutic area. Initial technical testing in vitro has now been successfully completed, and certain circVec candidates have been selected for further testing in vivo. CNS testing in circVec 3.2 and 4.0 has been ongoing at least since August 25 both internally and now also in specific therapeutic areas. Data has not been published. Yesterday's message confirms that in vitro testing for Big Pharma was a success. This does not exclude that they have their own in vivo studies ready also in 3.2 and 4.0, but not in these specific therapeutic areas. The message can be interpreted as a confirmation that CNS will come with good results, just as the heart and eye studies have delivered previously. What is better then than if the market also knows that Big Pharma has moved forward in CNS after ex vivo??
·29 min sittenI share your views, GreatReset. With yesterday's news in the bag, I become more certain that the longs will be the big winners in the end. Just wait and see. Congratulations to everyone who didn't get shaken out after the last weeks' rollercoaster. Yesterday's news is big news. 
·1 t sittenThis is exactly the type of message one wants to see in an early platform case. Circio maintains the timeline with proper progress: in vitro passed, candidates selected, the project moves on to in vivo – still fully funded by big pharma. It is a true external validation that circVec is interesting enough to be tested further. In a company like Circio, such steps are important. The platform is still alive, and it is moving forward.·32 min sitten · MuokattuThe fact that a feasibility study with Big Pharma, financed by them btw, has led to further collaboration and research... I mean, we can hardly get anything more validating than that at the present time. More of this is coming in the future. Correction: I just want to add that the research is moving into a more complex phase which both costs more and requires more resources. In Vivo is a significantly higher level when it comes to testing, and only a few are selected for this. Big Pharma would not have chosen to waste a lot of time, money, and resources on a platform that they believe does not have real value, both clinically and economically. The results from the feasibility study have therefore obviously been very good. We have a lot to look forward to in the future :)
·1 t sittenI believe it will open far above 10 kr on Monday after these incredibly good news. The issue was at kr 10.8, which is a suitable level. Since they fortunately are dropping the repair issue, so no one comes in via that route, there will be extra buying pressure. Opens 10.8 closes 14- ·1 t sitten · MuokattuInteresting article about the lack of suitable acquisition candidates for Big Pharma within in-vivo CAR-T: https://www.fiercebiotech.com/biotech/frenzied-feeding-playing-defense-and-disruption-lillys-kelonia-acquisition-and-future-vivo
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
10 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7 min sitten · MuokattuThe rights issue cancelled. It is not necessary to dilute the shareholders with a rights issue at kr. 10,80, especially not if the management also believes that the share price will rise. A share price increase will benefit all shareholders with an increase in value on a lower number of shares. Largest shareholder HØSE AS secured themselves against dilution in the 250 mill issue. They bought shares last Thursday at around 6-7. He stated that to Finansavisen. Everyone has had the opportunity to do the same, and if the price is under 10,80 at market open on Monday, the opportunity is still there. I interpret the timing of the announcement such that the management does not believe it will last going forward with a price under 10,80 and that they foresee a share price increase. Therefore, they announce while the price is still lower and Monday / Tuesday can change this. They don't need money. PS be prepared that the ASGCT announcement possibly won't come before Tuesday morning as the release time is 22.30 Norwegian time Monday as a nice person ENordfra reminded. Then the opportunity to buy is present all Monday if someone wishes it and the price is under 10,80. I believe that is the logic behind the timing of the announcement from the management last night.·2 min sittenWrong, they have enough until 2030 such decisions have been made at all general meetings in recent years. It can provide flexibility in negotiations on agreements combined with an ownership stake in the company. All options must be kept open even if they don't materialize..
- ·11 min sitten · MuokattuMonday - possibly after market close, due to the time difference, there will probably be a short message with info about what will be presented at ASGCT in May. Could yesterday evening's message be a premonition that CNS is the topic? This is an important sentence in yesterday's message: The project involves testing of Circio’s circVec circular RNA expression technology for delivery with AAV vectors in a specific therapeutic area. Initial technical testing in vitro has now been successfully completed, and certain circVec candidates have been selected for further testing in vivo. CNS testing in circVec 3.2 and 4.0 has been ongoing at least since August 25 both internally and now also in specific therapeutic areas. Data has not been published. Yesterday's message confirms that in vitro testing for Big Pharma was a success. This does not exclude that they have their own in vivo studies ready also in 3.2 and 4.0, but not in these specific therapeutic areas. The message can be interpreted as a confirmation that CNS will come with good results, just as the heart and eye studies have delivered previously. What is better then than if the market also knows that Big Pharma has moved forward in CNS after ex vivo??·29 min sittenI share your views, GreatReset. With yesterday's news in the bag, I become more certain that the longs will be the big winners in the end. Just wait and see. Congratulations to everyone who didn't get shaken out after the last weeks' rollercoaster. Yesterday's news is big news.
- ·1 t sittenThis is exactly the type of message one wants to see in an early platform case. Circio maintains the timeline with proper progress: in vitro passed, candidates selected, the project moves on to in vivo – still fully funded by big pharma. It is a true external validation that circVec is interesting enough to be tested further. In a company like Circio, such steps are important. The platform is still alive, and it is moving forward.·32 min sitten · MuokattuThe fact that a feasibility study with Big Pharma, financed by them btw, has led to further collaboration and research... I mean, we can hardly get anything more validating than that at the present time. More of this is coming in the future. Correction: I just want to add that the research is moving into a more complex phase which both costs more and requires more resources. In Vivo is a significantly higher level when it comes to testing, and only a few are selected for this. Big Pharma would not have chosen to waste a lot of time, money, and resources on a platform that they believe does not have real value, both clinically and economically. The results from the feasibility study have therefore obviously been very good. We have a lot to look forward to in the future :)
- ·1 t sittenI believe it will open far above 10 kr on Monday after these incredibly good news. The issue was at kr 10.8, which is a suitable level. Since they fortunately are dropping the repair issue, so no one comes in via that route, there will be extra buying pressure. Opens 10.8 closes 14
- ·1 t sitten · MuokattuInteresting article about the lack of suitable acquisition candidates for Big Pharma within in-vivo CAR-T: https://www.fiercebiotech.com/biotech/frenzied-feeding-playing-defense-and-disruption-lillys-kelonia-acquisition-and-future-vivo
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 480 | - | - | ||
| 515 | - | - | ||
| 82 | - | - | ||
| 393 | - | - | ||
| 7 050 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
10 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7 min sitten · MuokattuThe rights issue cancelled. It is not necessary to dilute the shareholders with a rights issue at kr. 10,80, especially not if the management also believes that the share price will rise. A share price increase will benefit all shareholders with an increase in value on a lower number of shares. Largest shareholder HØSE AS secured themselves against dilution in the 250 mill issue. They bought shares last Thursday at around 6-7. He stated that to Finansavisen. Everyone has had the opportunity to do the same, and if the price is under 10,80 at market open on Monday, the opportunity is still there. I interpret the timing of the announcement such that the management does not believe it will last going forward with a price under 10,80 and that they foresee a share price increase. Therefore, they announce while the price is still lower and Monday / Tuesday can change this. They don't need money. PS be prepared that the ASGCT announcement possibly won't come before Tuesday morning as the release time is 22.30 Norwegian time Monday as a nice person ENordfra reminded. Then the opportunity to buy is present all Monday if someone wishes it and the price is under 10,80. I believe that is the logic behind the timing of the announcement from the management last night.·2 min sittenWrong, they have enough until 2030 such decisions have been made at all general meetings in recent years. It can provide flexibility in negotiations on agreements combined with an ownership stake in the company. All options must be kept open even if they don't materialize..
- ·11 min sitten · MuokattuMonday - possibly after market close, due to the time difference, there will probably be a short message with info about what will be presented at ASGCT in May. Could yesterday evening's message be a premonition that CNS is the topic? This is an important sentence in yesterday's message: The project involves testing of Circio’s circVec circular RNA expression technology for delivery with AAV vectors in a specific therapeutic area. Initial technical testing in vitro has now been successfully completed, and certain circVec candidates have been selected for further testing in vivo. CNS testing in circVec 3.2 and 4.0 has been ongoing at least since August 25 both internally and now also in specific therapeutic areas. Data has not been published. Yesterday's message confirms that in vitro testing for Big Pharma was a success. This does not exclude that they have their own in vivo studies ready also in 3.2 and 4.0, but not in these specific therapeutic areas. The message can be interpreted as a confirmation that CNS will come with good results, just as the heart and eye studies have delivered previously. What is better then than if the market also knows that Big Pharma has moved forward in CNS after ex vivo??·29 min sittenI share your views, GreatReset. With yesterday's news in the bag, I become more certain that the longs will be the big winners in the end. Just wait and see. Congratulations to everyone who didn't get shaken out after the last weeks' rollercoaster. Yesterday's news is big news.
- ·1 t sittenThis is exactly the type of message one wants to see in an early platform case. Circio maintains the timeline with proper progress: in vitro passed, candidates selected, the project moves on to in vivo – still fully funded by big pharma. It is a true external validation that circVec is interesting enough to be tested further. In a company like Circio, such steps are important. The platform is still alive, and it is moving forward.·32 min sitten · MuokattuThe fact that a feasibility study with Big Pharma, financed by them btw, has led to further collaboration and research... I mean, we can hardly get anything more validating than that at the present time. More of this is coming in the future. Correction: I just want to add that the research is moving into a more complex phase which both costs more and requires more resources. In Vivo is a significantly higher level when it comes to testing, and only a few are selected for this. Big Pharma would not have chosen to waste a lot of time, money, and resources on a platform that they believe does not have real value, both clinically and economically. The results from the feasibility study have therefore obviously been very good. We have a lot to look forward to in the future :)
- ·1 t sittenI believe it will open far above 10 kr on Monday after these incredibly good news. The issue was at kr 10.8, which is a suitable level. Since they fortunately are dropping the repair issue, so no one comes in via that route, there will be extra buying pressure. Opens 10.8 closes 14
- ·1 t sitten · MuokattuInteresting article about the lack of suitable acquisition candidates for Big Pharma within in-vivo CAR-T: https://www.fiercebiotech.com/biotech/frenzied-feeding-playing-defense-and-disruption-lillys-kelonia-acquisition-and-future-vivo
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 480 | - | - | ||
| 515 | - | - | ||
| 82 | - | - | ||
| 393 | - | - | ||
| 7 050 | - | - |
Välittäjätilasto
Dataa ei löytynyt